Alpha 1-antitrypsin deficiency epidemiology and demographics: Difference between revisions

	Alpha 1-antitrypsin deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Alpha 1-antitrypsin deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Alpha 1-antitrypsin deficiency epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Alpha 1-antitrypsin deficiency epidemiology and demographics
CDC on Alpha 1-antitrypsin deficiency epidemiology and demographics
Alpha 1-antitrypsin deficiency epidemiology and demographics in the news
Blogs on Alpha 1-antitrypsin deficiency epidemiology and demographics
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency epidemiology and demographics

VisualWikitext

Revision as of 11:00, 12 December 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Alpha 1-antitrypsin deficiency (A1AD) is more common in people of Northern European, Iberian, and Saudi Arabian descent. Most researchers believe it is markedly underrecognized.

Epidemiology and Demographics

People of northern European, Iberian and Saudi Arabian ancestry are at the highest risk for A1AD. Four percent carry the PiZ allele; between 1 in 625 and 1 in 2000 are homozygous.

<figure-inline><figure-inline><figure-inline></figure-inline></figure-inline></figure-inline>

It is estimated that between 80,000 – 1000,000 (~ 1 in 1,650 to 1 in 3,000) Americans have severe alpha-1 AT deficiency (PI ZZ phenotype).In a recent survey, the average time interval between the onset of pulmonary symptoms and time of diagnosis was 7.2 years. Additionally, 43% of patients see at least 3 physicians before the diagnosis is established, and 12% see between 6 and 10. Thus, most authors believe that alpha-1 AT deficiency is markedly underrecognized. Because there are genetic implications to the next generation, that diagnosis can assist in smoking prevention / cessation, and that treatment is now available, enhanced detection is essential.

Incidence

The incidence of AATD is estimated to be (1 per 5000 ) cases per 100,000 individuals worldwide.

Prevalence

The prevalence of AATD is estimated to be 70,000-100,000 cases annually. Alpha1-antitrypsin deficiency (AATD) is one of most common lethal genetic diseases among adult white population. AATD has estimated 117 million carriers and 3.4 million affected individuals.

Race

AATD is more prevalent among the white population.

Sex

Men and women are affected equally by AATD.

Age

The enzyme deficiency is congenital and has a bimodal symptomatic distribution. It can present in neonates as a cause of neonatal jaundice and hepatitis.In infants it can cause cholestatic jaundice and in children, hepatic cirrhosis or liver failure. AATD is also the leading condition requiring liver transplantation in children.

AATD leads to chronic liver disease in the fifth decade of life. Emphysema in AATD, is seen in nonsmokers in the fifth decade of life and during the fourth decade of life in smokers.

References

Template:WikiDoc Sources

@@ Line 11: / Line 11: @@
 <figure-inline><figure-inline><figure-inline>[[Image:PiZZ Europe.png|600x600px]]</figure-inline></figure-inline></figure-inline>
-It is estimated that between 80,000 – 1000,000 (~ 1 in 1,650 to 1 in 3,000) Americans have severe alpha-1 AT deficiency (PI ZZ phenotype). This is approximately the same prevalence as [[cystic fibrosis]].  Studies have also estimated that ~ 2-3% of patients with severe [[COPD]] ([[chronic obstructive pulmonary disease]]) have severe alpha-1 AT deficiency.  Given this relatively high prevalence, it is interesting to find that most clinicians perceive alpha-1 AT deficiency to be rare.  In fact, only ~ 4% of patients with the PI ZZ phenotype were identified by the medical community in one study. The remaining 96% of PI ZZ patients must therefore be asymptomatic, or symptomatic but have escaped detection.  In a recent survey, the average time interval between the onset of pulmonary symptoms and time of diagnosis was 7.2 years.  Additionally, 43% of patients see at least 3 physicians before the diagnosis is established, and 12% see between 6 and 10.  Thus, most authors believe that alpha-1 AT deficiency is markedly underrecognized.  Because there are genetic implications to the next generation, that diagnosis can assist in smoking prevention / cessation, and that treatment is now available, enhanced detection is essential.
+It is estimated that between 80,000 – 1000,000 (~ 1 in 1,650 to 1 in 3,000) Americans have severe alpha-1 AT deficiency (PI ZZ phenotype).In a recent survey, the average time interval between the onset of pulmonary symptoms and time of diagnosis was 7.2 years.  Additionally, 43% of patients see at least 3 physicians before the diagnosis is established, and 12% see between 6 and 10.  Thus, most authors believe that alpha-1 AT deficiency is markedly underrecognized.  Because there are genetic implications to the next generation, that diagnosis can assist in smoking prevention / cessation, and that treatment is now available, enhanced detection is essential.
-=== Frequency\ ===
-In United States, AATD is one of the most common lethal genetic diseases in adult white persons, with an incidence of 1/5000 individuals and prevalence of 70,000 to 100,000. About 25 million people carry atleast 1 deficient gene.
-''International''
-AATD  is most common in Northern European and Iberian descends . Among white persons worldwide, there are an estimated 117 million carriers and 3.4 million affected individuals.
+===Incidence ===
+The incidence of AATD is estimated to be (1 per 5000 ) cases per 100,000 individuals worldwide.
+=== Prevalence ===
+The prevalence of AATD is estimated to be 70,000-100,000 cases annually. Alpha1-antitrypsin deficiency (AATD) is one of most common lethal genetic diseases among adult white population. AATD has estimated 117 million carriers and 3.4 million affected individuals.
 === Race ===
-White individuals constitute an estimated 117 million carriers and 3.4 million affected patients. Racial groups other than white population are affected less frequently.
+AATD is more prevalent among the white population.
 === Sex ===
-Women and men are affected in equal numbers.
+Men and women are affected equally by AATD.
 === Age ===
-The enzyme deficiency is congenital and has a bimodal distribution with respect to symptoms. It can be seen in neonates as a cause of neonatal jaundice and hepatitis. It can present in infants as cholestatic jaundice and in children as hepatic cirrhosis or liver failure. AATD is also the leading underlying condition requiring liver transplantation in children.
+The enzyme deficiency is congenital and has a bimodal symptomatic distribution. It can present in neonates as a cause of neonatal jaundice and hepatitis.In infants it can cause cholestatic jaundice and in children, hepatic cirrhosis or liver failure. AATD is also the leading condition requiring liver transplantation in children.
-In adults, AATD leads to chronic liver disease in the fifth decade of life. As a cause of emphysema, it is seen in nonsmokers in the fifth decade of life and during the fourth decade of life in smokers.
+AATD leads to chronic liver disease in the fifth decade of life. Emphysema in AATD, is seen in nonsmokers in the fifth decade of life and during the fourth decade of life in smokers.
 ==References==